查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1530006

老年用药市场规模、份额、趋势分析报告：依治疗药物、疾病状态、通路、地区、细分市场预测，2024-2030年

Geriatric Medicine Market Size, Share & Trends Analysis Report By Therapeutics (Analgesics, Antihypertensive, Statins, Proton Pump Inhibitors), By Condition, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格
简介目录

老年医学市场的成长与趋势：

Grand View Research, Inc.的最新报告显示，到2030年，全球老年医学市场规模预计将达到2,600亿美元，2024年至2030年复合年增长率为7.5%。

世界老年人口的成长是世界各地医疗保健产业和政府面临的主要挑战之一，但事实证明这对老年医学市场来说是一个福音。

老年人群中各种目标疾病的盛行率上升、人口结构变化、生活方式相关风​​险因素的趋势增加、以及新兴经济体获得医疗保健和负担得起的医疗保健的机会显着下降，预计市场将出现高速增长。

在预测期内，老年族群中阿兹海默症盛行率的上升预计将成为老年药物市场的重要动力。 2015年，阿兹海默症国际组织发布的估计显示，约有4,700万人患有失智症，而这一数字预计每20年就会增加一倍。此外，根据阿兹海默症协会发布的估计，美国540 万美国中约有 520 万（96.3%）年龄在 65 岁或以上。

为了缓解年龄、生活方式和经济发展等人口变数不利变化以及与人口老化相关的疾病趋势上升所带来的担忧，已开发地区不断向发展部门分配大量资源，改善医疗实践。

例如，美国、德国、英国和日本分别将GDP的17.1%、11.30%、9.10%和10.20%用于医疗保健支出，其中大部分资源用于开发新药，新软体的开发，居家医疗。

老年药物市场报告亮点

  • 在治疗类别中，2023年降血压治疗将占20.2%的份额。这些用于治疗高血压和低血压。市面上有各种抗高血压药物。
  • 2023年，北美以超过38.7%的销售份额占据老年用药市场的主导地位，这得益于发达的社会和医疗部门、最新药物的供应以及保险覆盖范围，这是因为有很多60岁以上的老年人。
  • 预计亚太地区将呈现最高成长率，2024 年至 2030 年复合年增长率将超过 9.1%。与已开发地区相比，亚太国家在目标疾病的经济负担、医疗保健可近性、健康保险以及公共和私人医疗支出比例等方面存在显着差异。
  • 预计中国和印度等国家的老年人口将大幅增加，这一因素预计将在预测期内老年药物市场呈现上升趋势。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章全球老年医学市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 全球老年医学市场分析工具
    • 波特的分析
    • PESTEL分析

第四章 全球老年用药市场：治疗药物、估算及趋势分析

  • 细分仪表板
  • 全球老年医学市场：2023年及2030年治疗药物波动分析
  • 止痛药
  • 抗高血压药
  • 他汀类药物
  • 抗糖尿病药
  • 质子帮浦抑制剂 (PPI)
  • 抗凝血物
  • 抗精神病药
  • 其他的

第五章全球老年用药市场：病理、估计与趋势分析

  • 细分仪表板
  • 全球老年医学市场：2023年及2030年病理变化分析
  • 心血管疾病
  • 关节炎与骨骼健康
  • 神经系统疾病
  • 癌症
  • 糖尿病与代谢紊乱
  • 呼吸系统疾病
  • 其他的

第六章 全球老年用药市场：通路、估算与趋势分析

  • 细分仪表板
  • 全球老年用药市场：2023年及2030年通路波动分析
  • 医院药房
  • 零售药房
  • 在线的

第七章 全球老年用药市场：区域估计与趋势分析

  • 2023 年和 2030 年全球老年药物市场占有率（按地区），百万美元
  • 北美洲
    • 2018-2030年北美老年医学市场估计与预测
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030 年欧洲老年药物市场估计与预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030 年亚太地区老年医学市场估计与预测
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 2018-2030 年拉丁美洲老年医学市场估计与预测
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 2018-2030年中东和非洲老年医学市场估计与预测
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • AbbVie Inc.
    • Johnson &Johnson Services, Inc.
    • Merck and Co., Inc.
    • Pfizer, Inc.
    • Bristol-Myers Squibb Company
    • Sanofi
    • GSK plc
    • Takeda Pharmaceutical Company Limited
简介目录
Product Code: 978-1-68038-887-9

Geriatric Medicine Market Growth & Trends:

The global geriatric medicine market size is expected to reach USD 260.0 billion by 2030, registering a CAGR of 7.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increase in the global geriatric population is one of the major challenges for the healthcare industry and the governments across the globe, however, it has proven to be a boon for the geriatric medicine market.

The high market growth is anticipated on account of the rising prevalence of various target diseases in the geriatric population, the demographic shift, the upward trend in lifestyle-related risk factors, and the significantly improved access to affordable healthcare as well as medicine across the developing and emerging economies.

The rising prevalence of the Alzheimer's disease in the geriatric population is expected to serve as a high impact rendering driver for the geriatric medicine market over the forecast period. In 2015, as per the estimates published by the Alzheimer's disease International, nearly 47 million people have dementia and this number is expected to double after every 20 years. Furthermore, as per the estimates published by The Alzheimer's Association, in the U.S., out of the 5.4 million Americans living with the disease, nearly 5.2 million or 96.3% are aged 65 and above.

In order to mitigate the concerns arising due to the unfavorable shift in the demographic variables such as age, lifestyle patterns, economic development, coupled with the upward shift in the disease trends associated with the geriatric population, the developed regions have consistently improved their healthcare practices by allocating high amount of resources towards the healthcare and social development sectors.

For instance, the U.S., Germany, the UK, and Japan allocate 17.1%, 11.30%,9.10%,10.20%, of their GDP respectively towards healthcare expenditure and majority of these resources are channelized towards developing new drugs, new software, and building technology platforms for hospitals and home health services.

Geriatric Medicine Market Report Highlights:

  • In the therapeutic category, antihypertensive therapeutics accounted for a share of 20.2% in 2023. These are used for treating high and low blood pressure. There are a variety of antihypertensive drugs available in the market.
  • In 2023, North America dominated the geriatric medicine market with a revenue share of over 38.7% owing to the presence of well-developed social and healthcare sectors, the availability of the latest medicine, and insurance coverage coupled with the presence of a large number of people aged above 60 years.
  • Asia Pacific region is anticipated to exhibit the maximum growth rate at a CAGR of over 9.1% from the year 2024 to 2030. In comparison with the developed regions, the economic burden of the target diseases, the access to healthcare, health insurance and the percentage of public and private healthcare expenditures vary significantly in the Asia Pacific countries.
  • The countries such as China and India are expected to witness a significant rise in the elderly population base and this factor in turn is expected to create an upward trend in the geriatric medicine market over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Geriatric Medicine Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Global Geriatric Medicine Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Global Geriatric Medicine Market: Therapeutics Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Geriatric Medicine Market: Therapeutics Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Analgesics
    • 4.3.1. Analgesics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Antihypertensive
    • 4.4.1. Antihypertensive Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Statins
    • 4.5.1. Statins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Antidiabetic
    • 4.6.1. Antidiabetic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Proton Pump Inhibitors (PPI)
    • 4.7.1. Proton Pump Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Anticoagulant
    • 4.8.1. Anticoagulant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Antipsychotic
    • 4.9.1. Antipsychotic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Antidiabetic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Geriatric Medicine Market: Condition Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Geriatric Medicine Market: Condition Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Cardiovascular Disease
    • 5.3.1. Cardiovascular Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Arthritis and Bone Health
    • 5.4.1. Arthritis and Bone Health Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Neurological Disorders
    • 5.5.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Cancer
    • 5.6.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Diabetes and Metabolic Disorders
    • 5.7.1. Diabetes & Metabolic Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Respiratory Diseases
    • 5.8.1. Respiratory Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Geriatric Medicine Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Geriatric Medicine Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online
    • 6.5.1. Online Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Global Geriatric Medicine Market: Regional Estimates & Trend Analysis

  • 7.1. Global Geriatric Medicine Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. F. Hoffmann-La Roche Ltd.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. AbbVie Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Johnson & Johnson Services, Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Merck and Co., Inc.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Pfizer, Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Bristol-Myers Squibb Company
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Sanofi
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. GSK plc
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Takeda Pharmaceutical Company Limited
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives